Kathryn E. Beckermann, MD, PhD

Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.

Drs Moshe Ornstein and Mehmet Asim Bilen review updated data from the CheckMate 9ER and CLEAR trials investigating combination treatments for metastatic renal cell carcinoma.

Mehmet Asim Bilen, MD, presents a profile of a 65-year-old woman with metastatic renal cell carcinoma for discussion.

Moshe Ornstein, MD, MA, starts a conversation on how patients with metastatic renal cell carcinoma are classified by risk, and how risk category influences approaches to systemic therapy.

Kathryn E. Beckermann, MD, PhD, discusses the evolving adjuvant treatment setting for renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses the need for biomarkers in frontline renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Kathryn E. Beckermann, MD, PhD, discusses treatment selection in metastatic renal cell carcinoma.

The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.